Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 2, 2016

 

 

STERIS plc

(Exact Name of Registrant as Specified in Charter)

 

 

 

England and Wales   1-37614   98-1203539

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

Chancery House, 190 Waterside Road

Hamilton Industrial Park, Leicester LE5 1QZ

United Kingdom

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: +44 0 116 276 8636

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


ITEM 5.07. Submission of Matters to a Vote of Security Holders.

At the STERIS plc (the “Company”) 2016 Annual General Meeting of Shareholders (“Meeting”), held on August 2, 2016, shareholders voted on the matters specified below, with the final voting results as specified. According to the certified list of shareholders, there were 86,000,248 Ordinary Shares of the Company outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 62,787,463 Ordinary Shares or 73.01% of the outstanding Ordinary Shares of the Company, constituting a quorum.

 

1. The nominees named below were elected to the Board of Directors, each for a one-year term, and the results of the vote were as follows:

 

Nominee    Votes for      Votes against      Abstentions      Broker non-votes  

Richard C. Breeden

     58,591,461         582,059        35,553         3,578,390   

Cynthia L. Feldmann

     58,434,452         589,270        185,351         3,578,390   

Jacqueline B. Kosecoff

     59,028,589         131,689         48,795         3,578,390   

David B. Lewis

     57,744,115         1,415,504         49,454         3,578,390   

Sir Duncan K. Nichol

     59,011,509         149,933         47,631         3,578,390   

Walter M Rosebrough, Jr.

     59,046,213         83,215         79,645         3,578,390   

Mohsen M. Sohi

     58,558,774         610,178         40,121         3,578,390   

Dr. Richard M. Steeves

     58,879,811         132,243         197,019         3,578,390   

John P. Wareham

     59,025,603         134,535         48,935         3,578,390   

Loyal W. Wilson

     58,564,885         565,186         79,002         3,578,390   

Michael B. Wood

     59,064,739         96,851         47,483         3,578,390   

 

2. The results of a proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2017 were as follows:

 

Votes for

     58,477,151   

Votes against

     4,266,157   

Abstentions

     44,155   

 

3. The results of a proposal to appoint Ernst & Young LLP as the Company’s U.K. statutory auditor under the Act to hold office until the conclusion of the Company’s next Annual General Meeting were as follows:

 

Votes for

     58,823,252   

Votes against

     3,921,142   

Abstentions

     43,069   

 

4. The results of a proposal to authorize the Directors of the Company or the Audit Committee to determine the remuneration of Ernst & Young LLP as the Company’s U.K. statutory auditor were as follows:

 

Votes for

     60,085,857   

Votes against

     2,321,639   

Abstentions

     379,967   

 

5. The results of a proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 13, 2016, were as follows:

 

Votes for

     57,679,692   

Votes against

     1,440,427   

Abstentions

     88,954   

Broker non-votes

     3,578,390   


6. The results of a proposal to approve, on a non-binding advisory basis, the Directors’ Remuneration Report (other than the part containing the directors’ remuneration policy) for the period ended March 31, 2016 contained within the Company’s annual report and accounts for the year ended March 31, 2016 were as follows:

 

Votes for

     57,265,508   

Votes against

     1,423,145   

Abstentions

     520,420   

Broker non-votes

     3,578,390   

 

7. The results of a proposal to approve the Directors’ Remuneration Policy were as follows:

 

Votes for

     57,540,852   

Votes against

     1,146,127   

Abstentions

     522,094   

Broker non-votes

     3,578,390   

 

8. The results of a proposal to approve the STERIS plc Senior Executive Management Incentive Compensation Plan, Effective April 1, 2016, were as follows:

 

Votes for

     58,070,103   

Votes against

     1,019,634   

Abstentions

     119,336   

Broker non-votes

     3,578,390   

 

9. The results of a proposal to approve the STERIS plc 2006 Long-Term Equity Incentive Plan, as Amended and Restated Effective August 2, 2016, were as follows:

 

Votes for

     45,039,729   

Votes against

     14,086,690   

Abstentions

     82,654   

Broker non-votes

     3,578,390   

 

10. The results of a proposal to (a) authorize the Company to make off-market purchases (within the meaning of section 694 of the Companies Act 2006); (b) approve the share repurchase contracts in the forms produced to the Meeting and initialed by the Chairman for the purposes of identification to be used by the Company to repurchase its ordinary shares of £0.10 per share (the “Ordinary Shares”) pursuant to and in accordance with the terms set out therein; and (c) approve the list of counterparties with whom the Company may conduct such repurchase transactions, were as follows:

 

Votes for

     62,438,077   

Votes against

     202,681   

Abstentions

     146,705   

 

11. The results of a proposal to authorize the Company to make an off-market purchase (within the meaning of section 694 of the Companies Act 2006) of the one Ordinary Share of the Company held by STERIS Corporation, and approve a share repurchase contract in the form produced to the Meeting and initialed by the Chairman for the purposes of identification to be used to effect such repurchase, were as follows:

 

Votes for

     61,687,364   

Votes against

     424,542   

Abstentions

     675,557   


12. The results of a proposal to approve the deletion of Article 154(1) of the Company’s Articles of Association relating to business combinations and its replacement with the following:

“The adoption or authorisation of any Business Combination must be pre-approved with the sanction of an ordinary resolution of the Company. The foregoing vote shall be in addition to any class vote or other vote otherwise required by law, these Articles, or any agreement to which the Company is a party.”

were as follows:

 

Votes for

     59,017,156   

Votes against

     115,691   

Abstentions

     76,226   

Broker non-votes

     3,578,390   

 

13. The results of a proposal to ratify and confirm:

a. the payment of $0.25 per Ordinary Share interim dividend made by the Company on March 29, 2016 (the “Interim Dividend”) and the entry in the audited accounts of the Company for the fiscal year ended March 31, 2016, whereby distributable profits of the Company were appropriated to the payment of the Interim Dividend;

b. that any and all claims which the Company may have in respect of the payment of the Interim Dividend against its shareholders who appeared on the register of shareholders and/or against holders of depositary interests in respect of Ordinary Shares on the record date for the Interim Dividend be released effective as of March 29, 2016, and that a deed of release in favor of such persons be entered into by the Company in the form of the deed produced to the Meeting and initialed by the Chairman for the purposes of identification; and

c. that any and all claims which the Company has or may have against its directors (whether past, present or future) arising in connection with the payment of the Interim Dividend be released and that a deed of release in favor of such persons be entered into by the Company in the form of the deed produced to the Meeting and initialed by the Chairman for the purposes of identification,

were as follows:

 

Votes for

     58,995,330   

Votes against

     58,891   

Abstentions

     154,852   

Broker non-votes

     3,578,390   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STERIS plc
By          

/s/ J. Adam Zangerle

  J. Adam Zangerle
  Secretary

Date: August 3, 2016